AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AtriCure, Inc. (NASDAQ:ATRC) have received an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $52.4444.

Several brokerages recently issued reports on ATRC. Weiss Ratings reissued a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Canaccord Genuity Group increased their price objective on shares of AtriCure from $53.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. upped their target price on shares of AtriCure from $42.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Thursday, October 30th.

AtriCure Stock Performance

ATRC opened at $39.06 on Monday. The company has a 50 day simple moving average of $38.25 and a two-hundred day simple moving average of $36.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.87 and a quick ratio of 2.85. The firm has a market cap of $1.94 billion, a P/E ratio of -64.03 and a beta of 1.40. AtriCure has a 1-year low of $28.29 and a 1-year high of $43.18.

AtriCure (NASDAQ:ATRC) last released its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.10. The company had revenue of $134.27 million for the quarter, compared to analysts’ expectations of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.54%. AtriCure’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. Equities analysts forecast that AtriCure will post -0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Sven Wehrwein sold 4,967 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $38.00, for a total transaction of $188,746.00. Following the completion of the transaction, the director directly owned 34,374 shares of the company’s stock, valued at approximately $1,306,212. This represents a 12.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Justin J. Noznesky sold 5,166 shares of AtriCure stock in a transaction that occurred on Wednesday, November 26th. The stock was sold at an average price of $37.29, for a total value of $192,640.14. Following the completion of the sale, the insider directly owned 78,798 shares in the company, valued at approximately $2,938,377.42. The trade was a 6.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 18,166 shares of company stock worth $676,378. Corporate insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On AtriCure

A number of hedge funds have recently bought and sold shares of the business. Marks Group Wealth Management Inc raised its stake in shares of AtriCure by 36.8% in the second quarter. Marks Group Wealth Management Inc now owns 28,973 shares of the medical device company’s stock valued at $949,000 after acquiring an additional 7,788 shares during the period. Nicholas Company Inc. grew its holdings in AtriCure by 8.5% during the 2nd quarter. Nicholas Company Inc. now owns 192,635 shares of the medical device company’s stock valued at $6,313,000 after purchasing an additional 15,135 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in AtriCure in the 2nd quarter worth about $284,000. Squarepoint Ops LLC raised its position in AtriCure by 64.7% in the 2nd quarter. Squarepoint Ops LLC now owns 186,965 shares of the medical device company’s stock worth $6,127,000 after purchasing an additional 73,468 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in AtriCure by 1.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 755,537 shares of the medical device company’s stock worth $24,759,000 after purchasing an additional 7,731 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.